Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly versus triweekly docetaxel plus cisplatin concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
ChiCTR-TRC-10000774Phase 3Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Progression-free survival, Overall survival at 2 years and 2 more. Started Jan 2009; status: completed.
02
Drugs
docetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-10000774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10000774.